A better-than-expected first quarter and a goal of profitability and positive cash flow by the end of 2025 brought on a bit of a rally. For the most part, U.S. stocks had a good Monday, with the bellwether S&P 500 index confidently marching more than 1% higher. But BioCryst Pharmaceuticals (BCRX 18.43%) and its investors had a really good day, as the company delivered a first quarter that convincingly beat analyst estimates. The market rewarded this performance by pushing BioCryst's share price more than 18 ...